FDA gives AstraZeneca extension on cancer drug application
AstraZeneca
10,436.00p
12:54 24/12/24
0.13%
14.00p
The US Food and Drug Administration has given AstraZeneca and MSD a three month extension to review a new drug application for its prostate cancer treatment Lynparza.
Dow Jones I.A.
43,297.03
04:30 15/10/20
n/a
n/a
FTSE 100
8,136.99
12:59 24/12/24
n/a
n/a
FTSE 350
4,491.87
12:54 24/12/24
n/a
n/a
FTSE All-Share
4,449.61
13:14 24/12/24
n/a
n/a
Merck & Co. Inc.
$99.45
08:29 24/12/24
0.08%
$0.08
Pharmaceuticals & Biotechnology
20,055.90
12:54 24/12/24
0.25%
50.73
Both companies said they would continue to work with the FDA to facilitate the completion of the agency's review.